Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type

Michiyo Higashi, Norishige Yamada, Seiya Yokoyama, Sho Kitamoto, Kazuhiro Tabata, Chihaya Koriyama, Surinder Kumar Batra, Suguru Yonezawa

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.

Original languageEnglish (US)
Pages (from-to)101-106
Number of pages6
JournalPathobiology
Volume79
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Cholangiocarcinoma
Ovarian Neoplasms
Mucins
Survival Analysis
Liver Diseases
Epitopes
Multivariate Analysis
Monoclonal Antibodies
Peptides
Survival
Serum

Keywords

  • CA125
  • Cholangiocarcinoma
  • MUC16
  • Prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Higashi, M., Yamada, N., Yokoyama, S., Kitamoto, S., Tabata, K., Koriyama, C., ... Yonezawa, S. (2012). Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology, 79(2), 101-106. https://doi.org/10.1159/000335164

Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. / Higashi, Michiyo; Yamada, Norishige; Yokoyama, Seiya; Kitamoto, Sho; Tabata, Kazuhiro; Koriyama, Chihaya; Batra, Surinder Kumar; Yonezawa, Suguru.

In: Pathobiology, Vol. 79, No. 2, 01.02.2012, p. 101-106.

Research output: Contribution to journalArticle

Higashi, M, Yamada, N, Yokoyama, S, Kitamoto, S, Tabata, K, Koriyama, C, Batra, SK & Yonezawa, S 2012, 'Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type', Pathobiology, vol. 79, no. 2, pp. 101-106. https://doi.org/10.1159/000335164
Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, Koriyama C et al. Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology. 2012 Feb 1;79(2):101-106. https://doi.org/10.1159/000335164
Higashi, Michiyo ; Yamada, Norishige ; Yokoyama, Seiya ; Kitamoto, Sho ; Tabata, Kazuhiro ; Koriyama, Chihaya ; Batra, Surinder Kumar ; Yonezawa, Suguru. / Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. In: Pathobiology. 2012 ; Vol. 79, No. 2. pp. 101-106.
@article{96ebf23995b14d4cb9c2a5d55b974171,
title = "Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type",
abstract = "Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48{\%} of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.",
keywords = "CA125, Cholangiocarcinoma, MUC16, Prognosis",
author = "Michiyo Higashi and Norishige Yamada and Seiya Yokoyama and Sho Kitamoto and Kazuhiro Tabata and Chihaya Koriyama and Batra, {Surinder Kumar} and Suguru Yonezawa",
year = "2012",
month = "2",
day = "1",
doi = "10.1159/000335164",
language = "English (US)",
volume = "79",
pages = "101--106",
journal = "Pathobiology",
issn = "1015-2008",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type

AU - Higashi, Michiyo

AU - Yamada, Norishige

AU - Yokoyama, Seiya

AU - Kitamoto, Sho

AU - Tabata, Kazuhiro

AU - Koriyama, Chihaya

AU - Batra, Surinder Kumar

AU - Yonezawa, Suguru

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.

AB - Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.

KW - CA125

KW - Cholangiocarcinoma

KW - MUC16

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84856175874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856175874&partnerID=8YFLogxK

U2 - 10.1159/000335164

DO - 10.1159/000335164

M3 - Article

C2 - 22286058

AN - SCOPUS:84856175874

VL - 79

SP - 101

EP - 106

JO - Pathobiology

JF - Pathobiology

SN - 1015-2008

IS - 2

ER -